PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERENUMAB (AMG 334) IN MIGRAINE PREVENTION: PRIMARY RESULTS OF THE STRIVE TRIAL

被引：3
|
作者：
Goadsby, Peter J. [1 ]
Reuter, Uwe [2 ]
Bonner, Jo [3 ]
Broessner, Gregor [4 ]
Hallstrom, Yngve [5 ]
Zhang, Feng [6 ]
Sapra, Sandhya [7 ]
Picard, Hernan [8 ]
Mikol, Daniel [8 ]
Lenz, Robert [8 ]
机构：
[1] Kings Coll London, London, England
[2] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany
[3] Mercy Res, St Louis, MO USA
[4] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria
[5] Stockholm Neuro Ctr, Stockholm, Sweden
[6] Amgen Inc, Global Biostat Sci, Thousand Oaks, CA 91320 USA
[7] Amgen Inc, Global Hlth Econ, Thousand Oaks, CA 91320 USA
[8] Amgen Inc, Global Dev, Thousand Oaks, CA 91320 USA
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2017年 / 88卷 / 05期
关键词：
D O I：
10.1136/jnnp-2017-316074.62
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
62
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (AMG 334) in migraine prevention: Primary results of the STRIVE trial
    Reuter, Uwe
    Bonner, Jo
    Broessner, Gregor
    Hallstrom, Yngve
    Zhang, Feng
    Sapra, Sandhya
    Picard, Hernan
    Mikol, Daniel D.
    Lenz, Robert A.
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [2] Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (AMG 334) in migraine prevention: primary results of the STRIVE Trial
    Goadsby, P. J.
    Reuter, U.
    Bonner, J.
    Broessner, G.
    Hallstrom, Y.
    Zhang, F.
    Sapra, S.
    Picard, H.
    Mikol, D.
    Lenz, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 117 - 117
  • [3] Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention: Primary Results of the STRIVE Trial
    Goadsby, Peter
    Reuter, Uwe
    Bonner, Jo
    Broessner, Gregor
    Hallstrom, Yngve
    Zhang, Feng
    Sapra, Sandhya
    Picard, Hernan
    Mikol, Daniel
    Lenz, Robert
    NEUROLOGY, 2017, 89 (08) : E104 - E104
  • [4] Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention: Primary Results of the STRIVE Trial
    Goadsby, P. J.
    Reuter, U.
    Bonner, J.
    Broessner, G.
    Hallstrom, Y.
    Zhang, F.
    Sapra, S.
    Picard, H.
    Mikol, D. D.
    Lenz, R. A.
    HEADACHE, 2017, 57 : 128 - 129
  • [5] A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERENUMAB IN MIGRAINE PREVENTION: PRIMARY RESULTS OF THE ARISE TRIAL
    Dodick, David
    Ashina, Messoud
    Kudrow, David
    Lanteri-Minet, Michel
    Osipova, Vera
    Palmer, Kerry
    Picard, Hernan
    Mikol, Daniel D.
    Lenz, Robert A.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 (05):
  • [6] A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention
    Tepper, S. J.
    Dolezil, D.
    Ashina, M.
    Reuter, U.
    Brandes, J. L.
    Silberstein, S. D.
    Winner, P.
    Leonardi, D. K.
    Mikol, D. D.
    HEADACHE, 2017, 57 : 130 - 130
  • [7] PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERENUMAB (AMG 334) IN CHRONIC MIGRAINE PREVENTION
    Tepper, S.
    Widnell, K.
    Dolezil, D.
    Ashina, M.
    Reuter, U.
    Brandes, J. Lewis
    Silberstein, S.
    Winner, P.
    Leonardi, D.
    Mikol, D.
    CEPHALALGIA, 2016, 36 : 44 - 45
  • [8] Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
    Sun, Hong
    Dodick, David W.
    Silberstein, Stephen
    Goadsby, Peter J.
    Reuter, Uwe
    Ashina, Messoud
    Saper, Joel
    Cady, Roger
    Chon, Yun
    Dietrich, Julie
    Lenz, Robert
    LANCET NEUROLOGY, 2016, 15 (04): : 382 - 390
  • [9] A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention: Primary Results of the ARISE Trial
    Dodick, David
    Ashina, Messoud
    Kudrow, David
    Lanteri-Minet, Michel
    Osipova, Vera
    Paler, Kerry
    Picard, Hernan
    Mikol, Daniel
    Lenz, Robert
    NEUROLOGY, 2017, 89 (08) : E98 - E98
  • [10] A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: Primary results of the ARISE trial
    Ashina, M.
    Dodick, D.
    Kudrow, D.
    Lanteri-Minet, M.
    Osipova, V.
    Palmer, K.
    Picard, H.
    Mikol, D.
    Lenz, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 470 - 470
12345